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Numerical indices based on 
circulating tumor DNA for the 
evaluation of therapeutic response 
and disease progression in lung 
cancer patients
Kikuya Kato1, Junji Uchida2, Yoji Kukita1, Toru Kumagai2, Kazumi Nishino2, Takako Inoue2, 
Madoka Kimura2, Shigeyuki Oba3 & Fumio Imamura2
Monitoring of disease/therapeutic conditions is an important application of circulating tumor DNA 
(ctDNA). We devised numerical indices, based on ctDNA dynamics, for therapeutic response and disease 
progression. 52 lung cancer patients subjected to the EGFR-TKI treatment were prospectively collected, 
and ctDNA levels represented by the activating and T790M mutations were measured using deep 
sequencing. Typically, ctDNA levels decreased sharply upon initiation of EGFR-TKI, however this did 
not occur in progressive disease (PD) cases. All 3 PD cases at initiation of EGFR-TKI were separated from 
other 27 cases in a two-dimensional space generated by the ratio of the ctDNA levels before and after 
therapy initiation (mutation allele ratio in therapy, MART) and the average ctDNA level. For responses 
to various agents after disease progression, PD/stable disease cases were separated from partial 
response cases using MART (accuracy, 94.7%; 95% CI, 73.5–100). For disease progression, the initiation 
of ctDNA elevation (initial positive point) was compared with the onset of objective disease progression. 
In 11 out of 28 eligible patients, both occurred within ±100 day range, suggesting a detection of the 
same change in disease condition. Our numerical indices have potential applicability in clinical practice, 
pending confirmation with designed prospective studies.
Circulating tumor DNA (ctDNA) is the cell-free DNA released from dying cancer cells1, and represents an emerg-
ing field of cancer research. Because ctDNA appears more frequently in advanced cancers than in early cancers2 
and its level is generally considered to correlate with the tumor burden, monitoring of disease/therapeutic con-
ditions is regarded as the foremost application of ctDNA3. Usually, cancer-related mutations are identified in 
primary lesions, and these serve as markers to detect ctDNA. Therapy-resistant mutations of target genes were 
identified with several agents, and these may be used to monitor acquired resistance4–8.
In the case of advanced non-small cell lung cancer, ctDNA has been extensively explored for genotyping 
of EGFR. Due to a strong correlation between EGFR activating mutations and the efficacy of EGFR tyrosine 
kinase inhibitors (EGFR-TKIs)9,10, the detection of mutations is indispensable for therapeutic decision making. 
Introduction of the next-generation EGFR-TKIs11,12 targeting EGFR with the T790M13 resistant mutation neces-
sitates the genotyping of the T790M locus. ctDNA containing EGFR-activating mutations and that containing the 
T790M mutation can serve as a metric for all cancer cells and therapy-resistant cells, respectively. ctDNA analysis 
in the EGFR-TKI treatment is advantageous over that in treatments using the other agents, which requires the 
identification of marker mutations to follow the whole amount of ctDNA.
Observation of ctDNA dynamics is often subjective. To enable the objective evaluation of ctDNA dynamics, it 
is desirable to have simple numerical indices that summarize information of individual events. Such indices could 
be directly used in clinical practice once their utility is established. In the case of advanced cancer, evaluation of 
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therapeutic responses and disease progression is important from a clinical viewpoint. In addition, the comparison 
should be performed with data obtained from an unbiased patient population, simulating real clinical practice.
We constructed a detection system for EGFR mutations in ctDNA using deep sequencing with a massively 
parallel DNA sequencer5. This system is among the most intensively validated assay systems for ctDNA14. Using 
this system, we conducted a prospective exploratory study to follow temporal changes of ctDNA levels under a 
real clinical setting. The general features of the data were previously described15. In this report, we propose two 
numerical indices to extract relevant information from ctDNA dynamics for clinically important events. These 
are a numerical index for the evaluation of the therapeutic response, and an index to estimate the onset of disease 
progression. The performance of these indices was evaluated using the current standards, namely the Response 
Evaluation Criteria In Solid Tumors (RECIST)16. We demonstrate that these indices, particularly the therapeu-
tic response index, appear to be useful for studying ctDNA dynamics and should be further investigated with 
designed prospective studies.
Results
Patient and sample populations. In total, 52 patients participated in the study. The clinical character-
istics of this patient population are shown in Table 1. Patient information corresponds to the initiation of the 
EGFR-TKI treatment. The total number of blood samples was 530. The initial PCR amplification of EGFR exon 







Total number of cases 52 30 28
Sex
 Male 15 8 9
 Female 37 22 19
Age
 < 49 7 4 7
 50–59 8 5 4
 60–69 18 12 8
 70–79 17 7 8
 80–89 2 2 1
Stage
 IIIA 4 3 3
 IIIB 7 5 2
 IV 41 22 23
Mutation in biopsy sample
 exon 19 deletion 26 15 16
 L858R 23 14 11
 double 1 0 0
 L861Q 1 1 1
 G719C 1 0 0
Treatment before EGFR-TKI
 none 25 15 15
 surgery 3 1 3
 surgery/radiation 6 4 2
 surgery/chemotherapy 3 1 3
 radiation 7 5 2
 radiation/chemotherapy 4 1 2
 chemotherapy 4 3 1
EGFR-TKI
 gefitinib 41 22 24
 erlotinib 11 8 4
Effect of EGFR-TKI
 complete response (CR) 2 1 1
 partial response (PR) 36 23 22
 stable disease (SD) 7 1 2
 progressive disease (PD) 3 3 0
 not evaluable (NE) 4 2 3
Table 1.  Patient characteristics.
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Evaluation of the initial response to EGFR-TKI. We examined whether ctDNA dynamics could be used 
to evaluate the effect of EGFR-TKI treatment. As 5 patients lacked samples of the corresponding time points, 47 
patients were eligible for the analysis. Thirty patients (63.8%), whose initial levels of ctDNA exceeded the thresh-
old, were forwarded to the following quantitative analysis. Clinical characteristics of this patient subpopulation 
are shown in Table 1.
Mutation allele ratio in therapy (MART) is defined as the ratio of the PM score of the activating mutation after 
the initiation of therapy to that before the therapy, and is used as an index for therapeutic response. In the most 
cases, the initial high ctDNA levels decreased rapidly during the 2 weeks after the initiation of EGFR-TKI, but 
some cases continued to decrease until 4 weeks. For the calculation of MART, PM scores of 2 weeks and 4 weeks 
were used for 23 and 7 cases, respectively. MART is plotted in Supplementary Figure S1a, grouping the patients 
into PD and PR/complete response (CR)/SD/not evaluable (NE) cases. MART of all three PD cases exceeded 
0.1. On the contrary, MART exceeded 0.1 in only 6 out of 27 PR/CR/SD/NE cases. PM scores of these 9 cases are 
plotted in Supplementary Figure 1b. PM scores of PD cases were significantly higher than those of PR/CR cases. 
In the case of low ctDNA levels, the number of molecules in blood samples may fluctuate among sampling events, 
leading to fluctuations in PM scores. We therefore used the average of PM scores of the two assays as a second 
parameter to assess the reliability of MART. In a two-dimensional space generated by MART and PM scores, PD 
cases segregated in the upper right part of the plot (Fig. 1a).
Identification of cases eligible for long-term temporal analysis. Next, we examined whether ctDNA 
dynamics could be used to estimate the onset of disease progression during the EGFR-TKI treatment. The target 
period was from 1 month after the initiation of EGFR-TKI to the time of the detection of disease progression. 
Only patients who developed objective disease progression (PD) during the EGFR-TKI treatment were eligible 
for this analysis. 11 patients stopped the EGFR-TKI treatment before PD due to PD during the initial response 
(3 patients), death (3 patients), adverse effects (4 patients) and patient intension (1 patient). Six patients did not 
develop PD during the observation time (median, 358 days; minimum, 198 days; maximum, 747 days). The 
remaining 35 patients developed PD. Statistics of the time to develop PD in these cases is as follows: median, 335 
days; minimum, 57 days; maximum, 838 days.
To exclude cases with insufficient data, we chose cases that had 4 or more samples within a span of 300 days 
that included the PD time point. Twenty-eight cases met this criterion. Their clinical information is provided in 
Table 2 and summary statistics are in Table 1 (n = 351; sampling time interval: median = 43 days, lower quar-
tile = 22 days, upper quartile = 63 days).
Correlation between ctDNA dynamics and the onset of disease progression. Our previous study 
with a retrospective data set revealed that ctDNA levels of activating and T790M mutations were suppressed 
during the EGFR-TKI treatment until the onset of objective disease progression, but increased thereafter17. To 
compare ctDNA dynamics with objective disease progression identified by medical imaging, we defined the ini-
tial positive (IP) point as the initial time point when ctDNA levels starts to exceed the threshold after the sup-
pression. We identified the IP point for each patient and compared it with the time point of objective disease 
progression (PD point). Schematic representation of ctDNA dynamics is presented in Supplementary Figure S2 
to facilitate the understanding of IP and PD points. IP and PD points were shown as time intervals from the date 
of the initiation of EGFR-TKI, represented by days (Table 2). In patients 1–11, named “type I” patients, the time 
interval between IP and PD points was within ± 100 day range (IP from PD, Table 2), and there was a single data 
point or were no data points in the interval (Figs 2a–c and 3, Supplementary Figure S3a–g). Considering time 
Figure 1. Quantitative changes of ctDNA levels during therapeutic changes. Vertical axis, mutation 
allele ratio in therapy (MART). Horizontal axis, average of PM scores before and after initiation of therapies. 
(a) Response to the initial EGFR-TKI treatment. (b) Response to various therapies after the first disease 
progression. MART > 1000 and < 0.001 are converted to 1000 and 0.001, respectively.
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intervals between diagnostic tests, ctDNA dynamics and medical imaging were likely to capture the same change 
in disease condition. In 6 patients, the ctDNA level decreased upon initiation of new therapies (Figs 2b,c and 3, 
Supplementary Figure S3d,e,g).
In patients 12–15, named “type II” patients, the IP point preceded the PD point in time by more than 100 
days (IP from PD, Table 2), and there were two data points in the interval (Fig. 2d–f, Supplementary Figure S3h). 
In these patients, ctDNA dynamics diverged from medical imaging and elevated ahead of objective disease pro-
gression. In contrast to the uniformity of the ctDNA dynamics in type I patients, those in type II patients were 
more variable. In patient 12, the ctDNA levels constantly increased after the IP point (Fig. 2d). In patient 13, the 
ctDNA levels of the activating mutation elevated and maintained a certain level until the PD point, and then 
increased, with an accompanying increase in the T790M ctDNA (Fig. 2e). In patient 15, the pattern was similar to 
that of patient 13, but the ctDNA did not increase upon PD probably due to the intervention of cytotoxic agents 
(Supplementary Figure S3h). The temporal pattern of patient 14 was complicated partly due to the intervention 































1 2A type I IIIA 77 F L858R PR surgery/chemotherapy + 1115 659 659 0 − 
2 S3A type I IV 39 F exon 19 deletion PR curative radiation/chemotherapy + 437 372 308 −64
112 (exon 19 
deletion)
3 S3B type I IV 80 M L858R PR none + 440 296 347 51 − 
4 S3C type I IV 62 M exon 19 deletion PR none + 228 180 129 −51 − 
5 2B type I IV 69 F L858R PR none + 475 383 441 58 336 (T790M)
6 S3D type I IV 63 M exon 19 deletion PR curative surgery + 659 303 385 82 − 
7 S3E type I IV 68 F exon 19 deletion PR none + 229 172 171 −1 − 
8 S3F type I IIIB 39 F exon 19 deletion SD curative surgery − 718 159 252 93 − 
9 3 type I IV 37 M exon 19 deletion PR none + 1099 339 315 −24 − 
10 S3G type I IV 73 F L858R PR local radiation + 865 325 360 35 143 (T790M)
11 2C type I IV 78 F exon 19 deletion SD none − 563 299 215 −84 − 
12 2D type II IV 60 F exon 19 deletion PR chemotherapy + 434 336 161 −175 − 
13 2E type II IIIA 66 F L858R NE none + 283 238 119 −119 − 
14 2F type II IV 59 M exon 19 deletion PR none + 518 456 152 −304 − 
15 S3H type II IIIB 56 F L861Q PR none + 761 335 102 −233 − 
16 − type III IIIA 53 F exon 19 deletion PR surgery/chemotherapy − 700 558 n/a n/a − 
17 − type III IV 73 F L858R NE surgery/local radiation + 75 57 n/a n/a − 
18 − type III IV 61 F exon 19 deletion PR none − 489 375 n/a n/a − 
19 − type III IV 49 M L858R PR local radiation + 560 202 n/a n/a − 
20 − type III IV 49 M exon 19 deletion CR surgery − 874 838 n/a n/a − 
21 − type III IV 72 M L858R PR surgery radiataion + 796 421 n/a n/a − 
22 S4A type III IV 40 F exon 19 deletion PR none + 780 530 n/a n/a − 
23 S4B type III IV 62 F exon 19 deletion PR curative radiation/chemotherapy − 667 350 n/a n/a − 
24 − type III IV 74 M L858R PR none n/a 215 196 n/a n/a − 
25 − type III IV 41 F L858R NE curative surgery/chmotherapy n/a 1075 591 n/a n/a − 
26 − type III IV 73 F exon 19 deletion PR none − 554 290 n/a n/a − 
27 − type III IV 54 F L858R PR none + 303 290 n/a n/a − 




Table 2.  Clinical information of the patients subjected to temporal analysis and summary statistics of 
disease progression. (1) Days counted from initiation of EGFR-TKI. (2) Days counted from PD point to IP 
point. n/a, data not available or not applicable.
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Both the activating and the T790M mutations were elevated after the IP point in 8 patients (Figs 2a,b,d–f and 3, 
Supplementary Figure S3a,c,d). In these patients, the ctDNA level of T790M was constantly lower than that of the 
activating mutation, but often elevated later. We noted the solitary appearance of the T790M ctDNA in patient 11 
(Fig. 2c). In this case, the IP point was determined with the T790M ctDNA. We previously observed this type of 
cancer cell subpopulations17, which is not likely to be rare.
Patients 16–28 had no elevation related to PD, and were classified as “type III” (Table 2). Representative exam-
ples of the ctDNA dynamics are shown in Supplementary Figure 4. On the whole, the numbers of type I, type II, 
and type III patients were 11 (39.3%), 4 (14.3%) and 13 (46.4%), respectively. Solitary peak of activating mutations 
Figure 2. ctDNA dynamics of type I and II patients. Vertical axis, PM score for EGFR mutations (left) or 
protein concentration (μ g/mL) for CEA (right). Horizontal axis, days from initiation of EGFR-TKI. Horizontal 
lines at the top of each panel indicate treatment, vertical bars indicate initiation of therapy, and arrowheads 
indicate termination of therapy. Gray arrows below the horizontal lines indicate radiotherapy. Black arrowheads 
in the bottom of each panel indicate PD points. White arrowheads in each panel indicate IP points. Blue lines 
indicate activating mutations (exon 19 deletion or L858R). Red lines indicate T790M. Black broken lines indicate 
CEA. For patients who had no data exceeding LOD (PM score) or whose data were within the normal range 
(CEA), data were not presented in graphs. (a) Patient 1 (type I). (b) Patient 5 (type I). (c) Patient 11 (type I).  
(d) Patient 12 (type II). (e) Patient 13 (type II). (f) Patient 14 (type II). Abbreviations are as follows: CDDP, 
cisplatin; PEM, pemetrexed; CBDCA, carboplatin; nabPTX, nab-paclitaxel; PTX, paclitaxel; BEV, bevacizumab.
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appeared in patients 2 and 28 (Supplementary Figures 3a and 4c; Table 2). Although the peak could be regarded 
as a false positive of the IP point, its incidence was low, and therefore, it was not likely to evoke confusion in the 
identification of IP points.
We measured the level of carcinoembryonic antigen (CEA) in all cases. Increases of CEA in parallel with 
objective disease progression were observed in 9 out of the 28 patients (32.1%).
Response to various therapies. Disease progression is often accompanied by therapy changes. Patient 
9 had a long history of different therapies after the first disease progression, and is presented as an example 
(Fig. 3). This patient was treated with various agents including re-challenge of gefitinib. Both the activating 
mutation and the T790M ctDNA was elevated after the first PD, but these were soon suppressed with cytotoxic 
agents. During the treatment with various cytotoxic agents, the T790M ctDNA was suppressed, but the activat-
ing mutation was elevated in parallel with disease progression. Upon gefitinib, the T790M ctDNA increased, 
but AZD9291, EGFR-TKI targeted to T790M, suppressed the T790M. The ctDNA dynamics indicated that the 
T790M ctDNA represented a cancer cell population with drug susceptibility distinct from that of the major can-
cer cell population. Other patients with a long history of disease progression, that is patients 10 and 15, are shown 
in Supplementary Figures S3g,h.
All therapeutic changes after the first disease progression are presented in Table 3. These events were classified 
according to objective response, except for radiation therapy, and plotted in the two-dimensional space generated 
by MART and the average of PM scores (Fig. 1b). For the calculation, we used the time points adjacent to the 
initiation of a therapy. Relevant data are presented in Table 3. PD and SD cases segregated in the upper part of 
the plot, and PR cases segregated in the lower part with a single exception. Applying the threshold (MART = 0.1) 
deduced in the analysis of EGFR-TKI, the accuracy to discriminate between PD/SD and CR/PR was 94.7% (95% 
confidence interval, 73.5–100). Collecting the results of EGFR-TKI and these therapies, MART is the primary 
parameter to evaluate therapeutic response. The merit of the second parameter, that is, the average of the ctDNA 
levels of the two assays, was not clear in this data set, and may be dispensable. Unlike anti-cancer agents, radiation 
therapy did not change ctDNA dynamics, and segregated in the upper right part of the two-dimensional space.
Discussion
The main purpose of the numerical indices is to offer objective methods to correlate ctDNA dynamics with clini-
cal status; that is, therapeutic response and onset of objective disease progression. So far, the analysis of temporal 
changes in the ctDNA dynamics is simple observation of temporal patterns. We demonstrated here that subjective 
observation could be replaced with simple numerical indices. In particular, MART agreed well with the thera-
peutic response evaluated with the RECIST criteria. The results of this study are promising and may proceed to 
further confirmatory studies.
For the evaluation of the therapeutic response, MART served as the index and exhibited a good correlation 
with medical imaging. The second analysis on the various therapies may be regarded as a validation of the classi-
fier constructed using the results of the first analysis, demonstrating good predictability. The response of ctDNA 
is rapid because of its extremely short half-life18,19. Therefore, its main advantage over medical imaging is the early 
access to information. For example, in the case of initial EGFR-TKI, the ctDNA data for most cases was obtained 
2 weeks after therapy initiation.
For the onset of disease progression, we devised an IP point as the index. In type I patients, the IP point was 
likely to indicate the same change in the disease condition as did the objective disease progression. In type II 
patients, the IP point preceded the onset of the objective disease progression. It was not clear whether the early 
elevation of the ctDNA level in type II patients was a sign of disease progression or a consequence of other 
changes in the disease condition. Although ctDNA dynamics may represent the disease condition more precisely, 
Figure 3. ctDNA dynamics of patient 9 (type I) with long observation time after the first disease 
progression. The details of panels are the same as those in Fig. 2. Abbreviations are as follows: DOC, docetaxel; 
AMR, amurubicin.
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the presence of type II patients introduces some uncertainty to the predictability of the IP index. We note that the 
current border between types I and II is temporary, and we need to examine this issue in further detail.
Importantly, the ctDNA level of the activating mutations is more informative than that of T790M, and it uses 
both the MART and the IP point in most cases. The T790M ctDNA, which represents a part of the cancer cell 
population, is useful for identifying subpopulations with unique characteristics, but ctDNA levels of activating 
mutations are indispensable for the entire view of the ctDNA dynamics.
From a number of studies comparing genotyping of biopsies and peripheral blood14,20,21, the detection rate of 
ctDNA in advanced lung cancer is 60–70%. Our detection rate before the initial EGFR-TKI treatment was within 
this range. Our rate in the long-term temporal analysis was 53.6%, but this figure may be an underestimation, 
because approximately half of type III patients had a short observation time after the PD point. The presence 
of patients without detectable ctDNA would be the main disadvantage to reap clinical benefits. In contrast, the 
simplicity of the MART and the IP point would be an advantage over medical imaging, which often provides 
complicated information.
To apply this approach to other cancers, it is necessary to develop new technologies to detect multiple muta-
tions without screening of mutations in the primary lesions. We expect that recent advances in genomic technol-
ogies22 will solve this problem soon.
Methods
Patients. Lung cancer patients with EGFR activating mutations subjected to the first EGFR-TKI treat-
































5 2B type I L858R CDDP+ PEM 454 − 1 21 28 15057 65 0.004 NE
6 S3D type I exon 19 deletion
local radiation 
(brain) 527 − 20 68 n/a 9865 19738 2.000 radiation
6 S3D type I exon 19 deletion CBDCA+ nabPTX 644 − 49 15 42 19738 18724 0.949 PD
7 S3E type I exon 19 deletion CDDP+ PEM 172 − 1 57 57 2206 n.d. 0.000 PD
8 S3F type I exon 19 deletion CDDP+ PEM 209 − 5 43 93 n.d. 572 572 SD
9 3 type I exon 19 deletion
local radiation 
(brain) 358 − 8 17 n/a 4461 8619 1.932 radiation
9 3 type I exon 19 deletion
CBDCA+ PEM+ 
BEV 378 − 3 71 84 8619 261 0.030 PR
9 3 type I exon 19 deletion PEM 504 − 14 28 56 n.d. 1254 1254 PD
9 3 type I exon 19 deletion S1+ BEV 589 0 98 49 7171 3153 0.440 SD
9 3 type I exon 19 deletion gefitinib 729 0 41 56 464 639 1.377 PD
9 3 type I exon 19 deletion AZD9291 889 0 21 36 31119 157 0.005 PR
9 3 type I exon 19 deletion docetaxel 994 − 84 42 21 157 33872 216 PD
9 3 type I exon 19 deletion AMR 1064 − 28 35 21 33872 52361 1.546 PD
10 S3G type I L858R gefitinib+ GEM 353 − 28 7 10 n.d. 431 431 PD
10 S3G type I L858R gefitinib+ PEM 381 − 7 42 71 n.d. n.d. n/a NE
10 S3G type I L858R local radiation (illium) 531 − 45 19 n/a 326 2484 7.620 radiation
11 2C type I T790M CBDCA+ nabPTX 334 − 1 28 133 1797 29 0.016 PR
11 2C type I T790M erlotinib 518 − 30 45 47 n.d. n.d. n/a SD
12 2D type II exon 19 deletion erlotinib 336 − 56 28 61 10176 24447 2.402 PD
14 2D type II exon 19 deletion local radiation (bone) 495 − 18 4 n/a 13650 30448 2.231 radiation
14 2F type II exon 19 deletion CBDCA+ PTX+ BEV 510 − 11 8 n/a 30448 1789 0.059 NE
15 S3H type II L861Q CDDP+ PEM 363 − 2 32 76 620 n.d. 0.002 PR
15 S3H type II L861Q PEM 489 − 94 42 30 n.d. n.d. n/a SD
Table 3.  Response to various therapies after the first disease progression. (1) Days counted form initiation 
of EGFR-TKI. (2) Days counted form initiation of new treatment. n/a, not applicable; n.d., not detected. MART 
is calculated assgining 1 for"n.d." of single "n.d." cases. GEM, gemcitabine.
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Network Clinical Trials Registry UMIN000006764) from November 2011 to March 2014 in the Osaka Medical 
Center for Cancer and Cardiovascular Diseases. Written informed consent was obtained from all participants. 
This study was approved by the ethics committee of the Osaka Medical Center for Cancer and Cardiovascular 
Diseases. The methods were carried out in accordance with the approved guidelines.
Blood sampling. Blood sampling for the ctDNA assay was scheduled to be performed before the initiation 
of EGFR-TKI treatment, as well as two and four weeks (14 and 28 days) after the initiation. The timing allowed a 
leeway of ± 4 days, not counting holidays. Sampling after this period was intended each 2 months and was contin-
ued at least until the onset of objective disease progression and beyond this point when possible. Blood sampling 
was terminated on June 30 2014.
Clinical evaluation of therapeutic response and disease progression. Evaluation of response to 
therapy was done using RECIST version 1.1, and in the case of initial EGFR-TKI, approximately two months 
after treatment initiation. Evaluation of disease progression during the EGFR-TKI treatment was also based on 
the RECIST criteria. Additionally, criteria recommended in the Guidelines for Treatment and Diagnosis of Lung 
Cancer (the Japanese Lung Cancer Society) were applied.
ctDNA assay. The assay system searches mutations by deep sequencing, that is, sequencing a large num-
ber of gene fragments. Exons 19, 20 and 21 of the EGFR gene were independently amplified with PCR from 
patient plasma DNA, and deep sequencing was performed with the Ion Torrent PGM (Thermo Fisher Scientific, 
Waltham, MA, USA)23. A diagnostic score, termed the plasma mutation (PM) score, was defined as the number 
of reads with deletions (exon 19 deletions) or substitutions (exon 20, T790M; exon 21; L858R, L861Q) in 100,000 
reads. We deduced parameters corresponding to the limit of detection (LOD) and limit of quantification (LOQ)5, 
and used them to define a threshold for mutation detection. According to the results of a previous study14, the 
threshold for the initial level, that is, before the initiation of EGFR-TKI, was set as LOQ for exon 19 deletion and 
LOD for L858R. For the analysis of disease progression, we chose a conservative approach to set the threshold of 
detection as LOQ (PM score = 300). The multi-institute study14 conducted along with this study indicated that 
the possibility of false positive was negligible under this setting: the estimates of false-positive rates for exon 19 
deletion, L858R, and T790M were 2%, 0%, and 1%, respectively.
The laboratory procedures of the ctDNA assay were the same as previously described5 except that the current 
study used the latest versions of sequencing reagents. The assay was performed in the order of the sampling date 
from November 2012 to September 2014 at a rate of 12–24 samples per week.
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